Legend’s Carvykti (ciltacabtagene autoleucel) Receives the EC’s Approval for the Treatment of Relapsed and Refractory Multiple Mye...
Shots: The conditional approval was based on the P-Ib/II (CARTITUDE-1) study evalu...
Shots: The conditional approval was based on the P-Ib/II (CARTITUDE-1) study evalu...
Shots: The approval was based on the P-III (AGILE) study evaluating Tibovo + azaci...
Shots: NeoCart is a P-III cell therapy platform technology, a 3D tissue-engineered...
Shots: The BLA submission was based on the results from the P-I/II trial (n=171) &...
Shots: The EMA’s CHMP has adopted a positive opinion recommending approval o...
Shots: The opinion was based on P-III (BRAVE-AA1 & 2) trials...
Incisive News in 3 Shots.